
Alderley Park, Bruntwood SciTech’s life sciences and innovation campus, has welcomed F2G, a leading developer of antifungal therapies.
The business currently has staff based in Eccles and at MediaCityUK in Greater Manchester, and has taken almost 3,000 sq ft of lab space at Mereside, Alderley Park, in order to consolidate its operations in one purpose-designed space.
The consolidation supports the company’s accelerated development and regulatory plans following completion of a $100 million round of fundraising raise in late 2024. The company was visited last week at Alderley Park by Chief Medical Officer Professor Sir Chris Whitty to discuss the fungal disease landscape and barriers to antifungal drug research and development in the UK.
F2G joins the ranks of Alderley Park’s other life science innovators based on the site, from where it will advance development of therapies aimed at tackling rare and resistant fungal infections. It will benefit from being part of a highly connected ecosystem of life science and tech businesses, including Medicines Discovery Catapult, CellCentric, Globachem Discovery, Evotec, global software developers SAP, while Bruntwood SciTech’s wider customer network totals around 1,100 companies.
Kath Mackay, Chief Scientific Officer for Bruntwood SciTech, said:
“F2G’s decision to establish its UK base at Alderley Park is a strong endorsement of what the campus offers companies developing novel therapies . At a critical point in their growth journey, F2G recognised the value of consolidating their team within a campus that brings together state-of-the-art infrastructure, shared science services, a vibrant scientific community of collaborators and an established talent pool in one place.
“The new facility will give F2G the technical flexibility it needs to advance its clinical and preclinical development. As they work to advance first-in-class antifungals with the potential to transform outcomes for patients, being based at Alderley Park will support both development and future commercial readiness. It’s a place where pioneering science can move at pace, backed by infrastructure and an ecosystem that’s been purpose-built for exactly this kind of work.”
Dr Mike Birch, Chief Operating Officer, F2G, said:
“We are delighted to join the Alderley Park family. Relocating our laboratories and offices to a brand new, modern facility is very exciting and we look forward to discovering and developing more novel therapies here. Being located on the Alderley Park campus allows us to consolidate working relationships with current vendors and to begin new collaborations with innovative partners. As we grow, locating to Alderley Park will enhance our ability to recruit talent and provide a fantastic working environment.”